RxDoctor Payments Data

Jeana Whitacre

Family · Columbus, MSNPI 1326461500

Payments from drug & device makers

$1,362in general payments, 2019–2025

Across 75 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$439
  • AstraZeneca$272
  • Boehringer Ingelheim$112
  • Amgen$109
  • Novo Nordisk$83
  • Dexcom, Inc.$74
  • plus $273 from 11 others

What the payments were for

  • Food & beverage$1,362100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,362 in reported general payments places this provider in the 70th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$102,377
Medicare patients
281
Services billed
5,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$101,781
FarxigaDapagliflozin Propanediol95$98,804
MounjaroTirzepatide55$72,918
JardianceEmpagliflozin63$67,278
Tresiba Flextouch U-200Insulin Degludec59$44,211
EliquisApixaban17$19,430
Tresiba Flextouch U-100Insulin Degludec22$15,560
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$6,963
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,073
Potassium Chloride179$3,519
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate24$3,422
Gabapentin156$3,330
Rosuvastatin Calcium116$2,497
Atorvastatin Calcium433$2,485
Levothyroxine Sodium227$2,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$83$101,78196 claims
AstraZenecaFarxiga$272$98,80495 claims
Lilly USA, LLCMounjaro$439$72,91855 claims
Boehringer IngelheimJardiance$112$67,27863 claims
PfizerEliquis$16$19,43017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,007 family providers in Mississippi.

Other family in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →